HOXB13 G84E mutation in Finland: Population-based analysis of prostate, breast, and colorectal cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 3, 2013, Pages 452-460

  Laitinen, Virpi H ^a   Wahlfors, Tiina ^a   Saaristo, Leena ^a   Rantapero, Tommi ^a   Pelttari, Liisa M ^c   Kilpivaara, Outi ^d   Laasanen, Satu Leena ^b   Kallioniemi, Anne ^a   Nevanlinna, Heli ^c   Aaltonen, Lauri ^d   Vessella, Robert L ^f   Auvinen, Anssi ^a   Visakorpi, Tapio ^a   Tammela, Teuvo L J ^b   Schleutker, Johanna ^a,e  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

^f UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMEOBOX B13 PROTEIN; HOMEODOMAIN PROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ALLELIC IMBALANCE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENICITY; COLORECTAL CANCER; COMPUTER MODEL; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FINLAND; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLEASON SCORE; HOMEOBOX; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN STABILITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA; FEMALE; FINLAND; FOLLOW-UP STUDIES; GENOTYPE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876581228     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1000-T     Document Type: Article

References (49)

1. Finnish Cancer Registry. Cancer statistics; 2012. [updated 2012 Nov 13]. Available from: www.cancerregistry.fi.
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85. (Pubitemid 30451850)
3. Baker SG, Lichtenstein P, Kaprio J, Holm N. Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. Biometrics 2005;61:55-63. (Pubitemid 40380964)
4. Varghese JS, Easton DF. Genome-wide association studies in common cancers-what have we learnt? Curr Opin Genet Dev 2010;20: 201-9.
5. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011;20:3867-75.
6. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
7. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multistage genome-wide association study. Nat Genet 2011;43:785-91.
8. Gillanders EM, Xu J, Chang BL, Lange EM, Wiklund F, Bailey-Wilson JE, et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004;96:1240-7. (Pubitemid 39232715)
9. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005;77:219-29. (Pubitemid 41022705)
10. Cropp CD, Simpson CL, Wahlfors T, Ha N, George A, Jones MS, et al. Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22. Int J Cancer 2011;129:2400-7.
11. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012;366:141-9.
12. Krumlauf R. Hox genes in vertebrate development. Cell 1994;78: 191-201. (Pubitemid 24241088)
13. Huang L, Pu Y, Hepps D, Danielpour D, Prins GS. Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology 2007;148:1235-45.
14. Kim YR, Oh KJ, Park RY, Xuan NT, Kang TW, Kwon DD, et al. HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol Cancer 2010;9:124.
15. Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell 2009;36:405-16.
16. Ghoshal K, Motiwala T, Claus R, Yan P, Kutay H, Datta J, et al. HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS ONE 2010;5:e10338.
17. Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmstrom P, Nordenskjold B, et al. Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat 2008;107:225-34. (Pubitemid 350265690)
18. Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjold B, Stal O. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res 2010;12:R53.
19. Xu J, Lange EM, Lu L, Zheng SL,WangZ, Thibodeau SN, et al.HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2013;132:5-14.
20. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
21. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992;89:3367-71.
22. Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, et al. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with lateonset disease. Clin Cancer Res 2000;6:4810-5. (Pubitemid 32110424)
23. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 2011;13: R20.
24. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:1529-31.
25. Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H. Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 2000;36:1143-8. (Pubitemid 30330913)
26. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, et al. NAD(P)H:Quinone oxidoreductase 1 NQO1-2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008;40:844-53. (Pubitemid 351913646)
27. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7. (Pubitemid 28226275)
28. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18: 2193-200. (Pubitemid 30350210)
29. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 2007;81:559-75. (Pubitemid 47330214)
30. Olatubosun A, Valiaho J, Harkonen J, Thusberg J, Vihinen M. PON-P: integrated predictor for pathogenicity of missense variants.HumMutat 2012;33:1166-74.
31. Petersen B, Petersen TN, Andersen P, Nielsen M, Lundegaard C. A generic method for assignment of reliability scores applied to solvent accessibility predictions. BMC Struct Biol 2009;9:51.
32. Adamczak R, Porollo A, Meller J. Combining prediction of secondary structure and solvent accessibility in proteins. Proteins 2005;59: 467-75. (Pubitemid 40594291)
33. Capriotti E, Fariselli P, Rossi I, Casadio R. A three-state prediction of single point mutations on protein stability changes. BMC Bioinformatics 2008;9(Suppl 2):S6.
34. Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. Proteins 2006;62:1125-32. (Pubitemid 43364175)
35. Huang LT, Gromiha MM, Ho SY. iPTREE-STAB: interpretable decision tree based method for predicting protein stability changes upon mutations. Bioinformatics 2007;23:1292-3. (Pubitemid 47050547)
36. Peltonen L, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. Hum Mol Genet 1999;8:1913-23. (Pubitemid 29458670)
37. Service S, DeYoung J, Karayiorgou M, Roos JL, Pretorius H, Bedoya G, et al. Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nat Genet 2006;38:556-60.
38. Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet 2000;8:757-63.
39. Lynch HT, Boland CR, Gong G, Shaw TG, Lynch PM, Fodde R, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 2006;14:390-402.
40. Kestila M, Ikonen E, Lehesjoki AE. [Finnish disease heritage]. Duodecim 2010;126:2311-20.
41. Seppala EH, Ikonen T,Mononen N, Autio V, Rokman A, MatikainenMP, et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003;89:1966-70. (Pubitemid 37533278)
42. Cybulski C, Wokolorczyk D, Huzarski T, Byrski T, Gronwald J, Gorski B, et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006;43:863-6. (Pubitemid 44787112)
43. TischkowitzMD, Yilmaz A, Chen LQ, KaryadiDM,Novak D, Kirchhoff T, et al. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett 2008;270: 173-80.
44. Gronwald J, Cybulski C, Piesiak W, Suchy J, Huzarski T, Byrski T, et al. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer 2009;100:1508-12.
45. CHEK2 Breast Cancer Case-Control Consortium. CHEK2-1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74:1175-82.
46. Iniesta MD, Gorin MA, Chien LC, Thomas SM, Milliron KJ, Douglas JA, et al. Absence of CHEK2-1100delC mutation in families with hereditary breast cancer in North America. Cancer Genet Cytogenet 2010;202: 136-40.
47. Armenian HK, Lilienfeld AM, Diamond EL, Bross ID. Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet 1974;2:115-7.
48. Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 2011;60:691-8.
49. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9. (Pubitemid 14026148)